Loading...
NASDAQ: MTVA
MetaVia Inc.
Healthcare · Biotechnology
Market Cap
$3.26M
52w High
$23.10
52w Low
$1.34
P/E
-0.20
Volume
88.02K
Outstanding Shares
2.20M
Company profile
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
CEOHeon Kim Hyung
SectorHealthcare
IndustryBiotechnology
Employees9
IPO dateAug 5, 2016
Valuation
Forward P/E—
EV/EBITDA0.00
Enterprise value-$134.04K
Stock splits
Dec 5, 20251:11
Dec 21, 20231:8
Sep 13, 20221:30
Dec 31, 20191:25
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-347.9%▼365.49%vs FY2023
Analyst consensus
RatingBuy
Target price—
2
Buy
0
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 12, 2026
View
EPS
Actual vs estimate by quarter
Q2'25
ActualEst.
-$0.36
-$0.57
Q3'25
ActualEst.
-$0.26
-$0.32
Q4'25
ActualEst.
-$1.54
-$2.86
Q2'26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2'25
ActualEst.
—
—
Q3'25
ActualEst.
—
—
Q4'25
ActualEst.
—
—
Q2'26
Next Est.
—